Copyright © 1984 by the European Society of Cardiology.
© 1984 The European Society of Cardiology
Verapamil in acute myocardial infarction
THE DANISH STUDY GROUP ON VERAPAMIL IN MYOCARDIAL INFARCTIONReceived 28 December 1983; revised 19 March 1984; .
Address for correspondence. J. Fischer Hansen, MD, Medical Department II, Kommunehospitalet, DK-1399 Copenhagen K, Denmark.
Abstract
A double-blind study comparing verapamil with placebo was conducted in 16 Danish departments of internal medicine with coronary care units (CCU). All patients under 75 years of age admitted to the CCU with a suspicion of acute myocardial infarction (AMI) were evaluated. Of 7415 patients, 3917 were excluded on admission because of heart failure, heart block, other severely disabling diseases, or treatment with beta-blockers or calcium-antagonists.
Treatment was started on 3498 patients with 0.1 mg kg–1 verapamil i.v. and 120 mg perorally on admission followed by 120 mg t.i.d., or matched placebo. Treatment was continued for 6 months for patients ascertained to have had an AMI according to all three WHO criteria. Treatment was stopped in patients in whom these criteria were not fulfilled. Of 1436 patients with AMI, 717 were treated with verapamil and 719 with placebo After six months, 92 patients (12.8%) in the verapamil group and 100 patients (13.9%) in the placebo group were dead (NS). After 12 months the mortality rates were 15.2% and 16.4%, respectively (NS).
By six months after entry a total of 56 reinfarctions were recorded in 50 patients (7%) in the verapamil group and 66 reinfarctions in 60 patients (8.3%) in the placebo group (NS).
Key Words: Acute myocardial infarction • secondary prevention • calcium antagonist • verapamil
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. Kumar and C. P. Cannon Acute Coronary Syndromes: Diagnosis and Management, Part I Mayo Clin. Proc., October 1, 2009; 84(10): 917 - 938. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. L. Anderson, C. D. Adams, E. M. Antman, C. R. Bridges, R. M. Califf, D. E. Casey Jr, W. E. Chavey II, F. M. Fesmire, J. S. Hochman, T. N. Levin, et al. ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) Developed in Collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine J. Am. Coll. Cardiol., August 14, 2007; 50(7): e1 - e157. [Full Text] [PDF]
|
|
|
|
 |
|
 C. Rosendorff, H. R. Black, C. P. Cannon, B. J. Gersh, J. Gore, J. L. Izzo Jr, N. M. Kaplan, C. M. O'Connor, P. T. O'Gara, and S. Oparil REPRINT Treatment of Hypertension in the Prevention and Management of Ischemic Heart Disease: A Scientific Statement From the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention Hypertension, August 1, 2007; 50(2): e28 - e55. [Full Text] [PDF]
|
|
|
|
 |
|
 C. Rosendorff, H. R. Black, C. P. Cannon, B. J. Gersh, J. Gore, J. L. Izzo Jr, N. M. Kaplan, C. M. O'Connor, P. T. O'Gara, and S. Oparil Treatment of Hypertension in the Prevention and Management of Ischemic Heart Disease: A Scientific Statement From the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention Circulation, May 29, 2007; 115(21): 2761 - 2788. [Full Text] [PDF]
|
|
|
|
 |
|
 M. E van der Elst, H. Buurma, M. L Bouvy, and A. de Boer Drug Therapy for Prevention of Recurrent Myocardial Infarction Ann. Pharmacother., October 1, 2003; 37(10): 1465 - 1477. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. R. Black, W. J. Elliott, G. Grandits, P. Grambsch, T. Lucente, W. B. White, J. D. Neaton, R. H. Grimm Jr, L. Hansson, Y. Lacourciere, et al. Principal Results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) Trial JAMA, April 23, 2003; 289(16): 2073 - 2082. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J Abdulla, B Brendorp, C Torp-Pedersen, L Kober, and on behalf of the TRACE study group Does the electrocardiographic presence of Q waves influence the survival of patients with acute myocardial infarction? Eur. Heart J., June 2, 2001; 22(12): 1008 - 1014. [Abstract] [PDF]
|
|
|
|
 |
|
 J. R. Kizer and S. E. Kimmel Epidemiologic Review of the Calcium Channel Blocker Drugs: An Up-to-date Perspective on the Proposed Hazards Arch Intern Med, May 14, 2001; 161(9): 1145 - 1158. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. H. Opie First line drugs in chronic stable effort angina--the case for newer, longer-acting calcium channel blocking agents J. Am. Coll. Cardiol., November 15, 2000; 36(6): 1967 - 1971. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Braunwald, E. M. Antman, J. W. Beasley, R. M. Califf, M. D. Cheitlin, J. S. Hochman, R. H. Jones, D. Kereiakes, J. Kupersmith, T. N. Levin, et al. ACC/AHA guidelines for the management of patients with unstable angina and non-st-segment elevation myocardial infarction: A report of the american college of cardiology/ american heart association task force on practice guidelines (committee on the management of patients with unstable angina) J. Am. Coll. Cardiol., September 1, 2000; 36(3): 970 - 1062. [Full Text] [PDF]
|
|
|
|
|
|
G.Y.H. Lip, C. Lydakis, and D.G. Beevers Management of patients with myocardial infarction and hypertension Eur. Heart J., July 2, 2000; 21(14): 1125 - 1134. [PDF]
|
|
|
|
|
|
S. M. Zaacks, P. R. Liebson, J. E. Calvin, J. E. Parrillo, and L. W. Klein Unstable angina and non-Q wave myocardial infarction: does the clinical diagnosis have therapeutic implications? J. Am. Coll. Cardiol., January 1, 1999; 33(1): 107 - 118. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. J. Pepine, E. Handberg-Thurmond, R. G. Marks, M. Conlon, R. Cooper-Dehoff, P. Volkers, P. Zellig, and for The INVEST Investigators Rationale and design of the International Verapamil SR/Trandolapril Study (INVEST): an Internet-based randomized trial in coronary artery disease patients with hypertension J. Am. Coll. Cardiol., November 1, 1998; 32(5): 1228 - 1237. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 British Cardiac Society, British Hyperlipidaemia Association, British Hypertension Society, and endorsed by the British Diabetic Association Joint British recommendations on prevention of coronary heart disease in clinical practice Heart, July 1, 1998; 80(90002): 1S - 29. [Full Text]
|
|
|
|
 |
|
 R. H Mehta and K. A Eagle Fortnightly review: Secondary prevention in acute myocardial infarction BMJ, March 14, 1998; 316(7134): 838 - 842. [Full Text]
|
|
|
|
 |
|
 C. H. Hennekens, C. M. Albert, S. L. Godfried, J. M. Gaziano, and J. E. Buring Adjunctive Drug Therapy of Acute Myocardial Infarction -- Evidence from Clinical Trials N. Engl. J. Med., November 28, 1996; 335(22): 1660 - 1668. [Full Text] [PDF]
|
|
|
|
|
|
S Galatius-Jensen, J Launbjerg, L S. Mortensen, and J F. Hansen Sex related differences in short and long term prognosis after acute myocardial infarction: 10 year follow up of 3073 patients in database of first Danish verapamil infarction trial BMJ, July 20, 1996; 313(7050): 137 - 140. [Abstract] [Full Text]
|
|
|
|
|
|
L. H. Opie and F. H. Messerli Nifedipine and Mortality : Grave Defects in the Dossier Circulation, September 1, 1995; 92(5): 1068 - 1073. [Full Text]
|
|
|
|
|
|
J. Z. Ayanian, P. J. Hauptman, E. Guadagnoli, E. M Antman, C. L. Pashos, and B. J. McNeil Knowledge and Practices of Generalist and Specialist Physicians Regarding Drug Therapy for Acute Myocardial Infarction N. Engl. J. Med., October 27, 1994; 331(17): 1136 - 1142. [Abstract] [Full Text]
|
|
|
|
|
|
J Launbjerg, P Fruergaard, J K Madsen, L S Mortensen, and J F Hansen Ten year mortality in patients with suspected acute myocardial infarction BMJ, May 7, 1994; 308(6938): 1196 - 1199. [Abstract] [Full Text]
|
|
|
|
|
|
J. F. Hansen Secondary Prevention With Calcium Antagonists After a Myocardial Infarction Arch Intern Med, October 11, 1993; 153(19): 2277 - 2281. [Abstract] [PDF]
|
|
|
|
|
|
U. Goldbourt, S. Behar, H. Reicher-Reiss, M. Zion, L. Mandelzweig, and E. Kaplinsky Early Administration of Nifedipine in Suspected Acute Myocardial Infarction: The Secondary Prevention Reinfarction Israel Nifedipine Trial 2 Study Arch Intern Med, February 8, 1993; 153(3): 345 - 353. [Abstract] [PDF]
|
|
|
|
 |
|
 J. J. Popma and E. J. Topol Adjuncts to Thrombolysis for Myocardial Reperfusion Ann Intern Med, July 1, 1991; 115(1): 34 - 44. [Abstract] [PDF]
|
|
|
|
|
|
A. E. Skolnick and W. H. Frishman Calcium Channel Blockers in Myocardial Infarction Arch Intern Med, July 1, 1989; 149(7): 1669 - 1677. [Abstract] [PDF]
|
|
|
|
 |
|
 B. W. Johansson, O. Hansen, S. Juul-Moller, and O. Svensson Adrenaline-Induced Changes in Serum Electrolytes, ECG, and Blood Pressure, with Ca-Blockade Pretreatment Angiology, April 1, 1988; 39(4): 345 - 354. [Abstract] [PDF]
|
|